Histamine H3 Receptor Isoforms: Insights from Alternative Splicing to Functional Complexity
BiomoleculesAlternative splicing significantly enhances the diversity of the G protein-coupled receptor (GPCR) family, including the histamine H3 receptor (H3R).
Meichun Gao +3 more
doaj +1 more source
0615 Pitolisant in Combination With Other Medications for the Management of Narcolepsy [PDF]
, 2019 Karl Doghramji +7 more
openalex +1 more source
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials [PDF]
, 2021 Nathaniel F. Watson +6 more
openalex +1 more source
Wpływ objawów i leczenia narkolepsji na życie seksualne - aktualne dowody i doniesienia naukowe [PDF]
Introduction: Narcolepsy (NT) can manifest as excessive daytime sleepiness (EDS), cataplexy, hypnagogic (HHG) and hypnopompic (HHP) hallucinations, sleep paralysis, orgasmolepsy – all of which may affect patients\u27 functioning. The aim of the study was
Dyzma-Kasprzak, Agnieszka +7 more
core +2 more sources
A Review of Current and Future Pharmacologic Treatments for Narcolepsy
European PsychiatryIntroduction Narcolepsy is a rare but disabling neurological disorder involving disruption of the sleep-wake cycle that is often under- or misdiagnosed (Barateau L, et al. J Sleep Res. 2022;31(4):e13631).
P. Chue +4 more
doaj +1 more source
SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany [PDF]
Purpose Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies
Benes, Heike +6 more
core +1 more source
0868 Long-Term Safety and Effectiveness of Pitolisant Use in Adult Patients with Idiopathic Hypersomnia (IH) [PDF]
Yves Dauvilliers +11 more
openalex +1 more source
Pitolisant Evaluation in Patients with OSA and Treated by NCPAP but Still Complaining of Excessive Daytime Sleepiness (EDS) Eudract n°: 2009-017248-14 [PDF]
, 2020 Jean‐Louis Pépin +7 more
openalex +1 more source
Efficacy of Pitolisant 20 mg in Reducing Excessive Daytime Sleepiness and Fatigue in Patients with Obstructive Sleep Apnoea Syndrome: An Individual Patient Data Meta-analysis [PDF]
, 2021 Philippe Lehert
openalex +1 more source